Similar articles

• No deal in sight on cheap drugs for poor countries.

  Fleck F. Fleck F. BMJ. 2003 Mar 1;326(7387):465. doi: 10.1136/bmj.326.7387.465/a. BMJ. 2003. PMID: 12609924 Free PMC article. No abstract available.
• [How are prices for important drugs stipulated in poor countries?].

  Lien L. Lien L. Tidsskr Nor Laegeforen. 2003 Apr 3;123(7):958-9. Tidsskr Nor Laegeforen. 2003. PMID: 12737074 Norwegian. No abstract available.
• TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.

  't Hoen E. 't Hoen E. Chic J Int Law. 2002 Spring;3(1):27-46. Chic J Int Law. 2002. PMID: 15709298 No abstract available.
• The concept of essential medicines: lessons for rich countries.

  Hogerzeil HV. Hogerzeil HV. BMJ. 2004 Nov 13;329(7475):1169-72. doi: 10.1136/bmj.329.7475.1169. BMJ. 2004. PMID: 15539676 Free PMC article. Review.
• Spurious and counterfeit drugs: a growing industry in the developing world.

  Gautam CS, Utreja A, Singal GL. Gautam CS, et al. Postgrad Med J. 2009 May;85(1003):251-6. doi: 10.1136/pgmj.2008.073213. Postgrad Med J. 2009. PMID: 19520877 Review.